Venture capitalists – validate therapeutic potential independently before investing

Pharmaceutical executives and board members – analyze objectivity and validity of in-house and potential in-licensing evaluations

Large investors – insure that drug discovery objectives are aligned with shareholders’ interests (reward rate of clinical compound approvals by FDA, not number of compounds advancing through the pipeline)